• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

基于解剖位置的转移性淋巴结密度是否影响肺癌患者的预后?

Does anatomical location-based metastatic lymph node density affect prognosis in lung cancer patients?

作者信息

Aksoy Yunus, Çıtak Necati, Obuz Çiğdem, Metin Muzaffer, Sayar Adnan

机构信息

Thoracic Surgery, Yedikule Chest Diseases and Thoracic Surgery Training and Research Hospital, Istanbul, Turkey.

Thoracic Surgery, Bakirkoy Dr Sadi Konuk Training and Research Hospital, Istanbul, Turkey.

出版信息

Interact Cardiovasc Thorac Surg. 2021 Oct 4;33(4):541-549. doi: 10.1093/icvts/ivab119.

DOI:10.1093/icvts/ivab119
PMID:34000035
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC8691707/
Abstract

OBJECTIVES

The newly proposed N subclassification (new-N) was compared with the combined anatomical location and ratio of the number of metastatic lymph nodes to the total number of resected lymph nodes (anatomic-LNR) in terms of prognosis in resected lung cancer patients.

METHODS

Between 2005 and 2018, 961 patients who underwent lung cancer resection were catergorized into the pN1-single (N1a; n = 281), pN1-multiple (N1b; n = 182), pN2-single with skip metastasis (N2a1; n = 116), pN2-single with N1 metastasis (N2a2; n = 222) and pN2-multiple (N2b; n = 160) groups based on new-N. The optimal cut-off points for survival in pN1 and pN2 patients were determined using the best sensitivity and specificity scores, calculated using receiver operating characteristic analysis.

RESULTS

The difference in survival between N1a and N1b patients was statistically significant (P = 0.001), but there was no significant difference in the survival rates of N1b and N2a1 (P = 0.52). The survival curves for N2a1 and N2a2 patients almost overlapped (P = 0.143). N2a2 patients showed a better survival rate than N2b patients, with no significant difference (P = 0.132). The cut-off points for LNR were 0.10 and 0.25 for pN1 and pN2 patients, respectively, according to receiver operating characteristic analysis for survival. Based on receiver operating characteristic analysis, pN patients were categorized into the N1-lowLNR (n = 232), N1-highLNR (n = 231), N2-lowLNR (n = 266) and N2-highLNR (n = 232) groups. The 5-year survival rate was 62.9%, 49.8%, 41.1% and 27.1% for N1-lowLNR, N1-highLNR, N2-lowLNR and N2-highLNR, respectively (P < 0.001).

CONCLUSIONS

LowLNR is associated with better survival than highLNR in resected lung cancer patients. Anatomic-LNR shows a high discriminatory power for prognosis.

摘要

目的

比较新提出的N亚分类(新N)与切除的肺癌患者的转移淋巴结数量与切除的淋巴结总数之比联合解剖位置(解剖学LNR)在预后方面的差异。

方法

2005年至2018年间,961例行肺癌切除术的患者根据新N被分为pN1单站(N1a;n = 281)、pN1多站(N1b;n = 182)、pN2单站伴跳跃转移(N2a1;n = 116)、pN2单站伴N1转移(N2a2;n = 222)和pN2多站(N2b;n = 160)组。使用受试者工作特征分析计算的最佳敏感性和特异性分数确定pN1和pN2患者生存的最佳截断点。

结果

N1a和N1b患者的生存率差异具有统计学意义(P = 0.001),但N1b和N2a1患者的生存率无显著差异(P = 0.52)。N2a1和N2a2患者的生存曲线几乎重叠(P = 0.143)。N2a2患者的生存率高于N2b患者,但差异不显著(P = 0.132)。根据生存的受试者工作特征分析,pN1和pN2患者的LNR截断点分别为0.10和0.25。根据受试者工作特征分析,pN患者被分为N1低LNR(n = 232)、N1高LNR(n = 231)、N2低LNR(n = 266)和N2高LNR(n = 232)组。N1低LNR、N1高LNR、N2低LNR和N2高LNR组的5年生存率分别为62.9%、49.8%、41.1%和

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c1d6/8691707/5301977fc9e7/ivab119f4.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c1d6/8691707/5301977fc9e7/ivab119f4.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c1d6/8691707/5301977fc9e7/ivab119f4.jpg

相似文献

1
Does anatomical location-based metastatic lymph node density affect prognosis in lung cancer patients?基于解剖位置的转移性淋巴结密度是否影响肺癌患者的预后?
Interact Cardiovasc Thorac Surg. 2021 Oct 4;33(4):541-549. doi: 10.1093/icvts/ivab119.
2
The International Association for the Study of Lung Cancer Lung Cancer Staging Project: Proposals for the Revision of the N Descriptors in the Forthcoming 8th Edition of the TNM Classification for Lung Cancer.国际肺癌研究协会肺癌分期项目:对即将发布的第 8 版肺癌 TNM 分类中 N 描述符修订的建议。
J Thorac Oncol. 2015 Dec;10(12):1675-84. doi: 10.1097/JTO.0000000000000678.
3
External validation of the N descriptor in the proposed tumour-node-metastasis subclassification for lung cancer: the crucial role of histological type, number of resected nodes and adjuvant therapy.肺癌拟用的肿瘤-淋巴结-转移亚分类中N描述符的外部验证:组织学类型、切除淋巴结数量及辅助治疗的关键作用
Eur J Cardiothorac Surg. 2020 Dec 1;58(6):1236-1244. doi: 10.1093/ejcts/ezaa215.
4
New N1/N2 classification and lobe specific lymphatic drainage: Impact on survival in patients with non-small cell lung cancer treated with surgery.新的 N1/N2 分类和叶特异性淋巴引流:对手术治疗非小细胞肺癌患者生存的影响。
Lung Cancer. 2021 Jan;151:84-90. doi: 10.1016/j.lungcan.2020.11.005. Epub 2020 Nov 16.
5
Validation of the 8th Edition Nodal Staging and Proposal of New Nodal Categories for Future Editions of the TNM Classification of Non-Small Cell Lung Cancer.第 8 版淋巴结分期的验证及对未来非小细胞肺癌 TNM 分类版本中新淋巴结分类的建议。
Ann Surg Oncol. 2021 Aug;28(8):4510-4516. doi: 10.1245/s10434-020-09461-y. Epub 2021 Jan 2.
6
Feasibility of nodal classification for non-small cell lung cancer by merging current N categories with the number of involved lymph node stations.通过将当前 N 类别与受累淋巴结站数合并,对非小细胞肺癌进行淋巴结分类的可行性。
Thorac Cancer. 2019 Jul;10(7):1533-1543. doi: 10.1111/1759-7714.13094. Epub 2019 Jun 17.
7
Recommended Change in the N Descriptor Proposed by the International Association for the Study of Lung Cancer: A Validation Study.国际肺癌研究协会提出的 N 描述符的建议更改:验证研究。
J Thorac Oncol. 2019 Nov;14(11):1962-1969. doi: 10.1016/j.jtho.2019.07.034. Epub 2019 Aug 20.
8
Postoperative radiotherapy option based on mediastinal lymph node reclassification for patients with pN2 non-small-cell lung cancer.基于纵隔淋巴结重新分类的 pN2 非小细胞肺癌患者术后放疗选择。
Curr Oncol. 2020 Jun;27(3):e283-e293. doi: 10.3747/co.27.5899. Epub 2020 Jun 1.
9
A Proposal for Combination of Lymph Node Ratio and Anatomic Location of Involved Lymph Nodes for Nodal Classification in Non-Small Cell Lung Cancer.非小细胞肺癌淋巴结分类中淋巴结比例与阳性淋巴结解剖位置联合应用的建议。
J Thorac Oncol. 2016 Sep;11(9):1565-73. doi: 10.1016/j.jtho.2016.05.004. Epub 2016 May 17.
10
A proposal for combination of total number and anatomical location of involved lymph nodes for nodal classification in non-small cell lung cancer.提出一种非小细胞肺癌淋巴结分类的方法,即结合淋巴结总数和受累淋巴结的解剖位置。
Chest. 2013 Jun;143(6):1618-1625. doi: 10.1378/chest.12-0750.

引用本文的文献

1
Risk factors and clinical risk stratification of distant metastasis in early-stage lung cancer in never smokers.从不吸烟者早期肺癌远处转移的危险因素及临床风险分层
World J Surg Oncol. 2025 Jun 18;23(1):238. doi: 10.1186/s12957-025-03892-1.
2
A clinical model to predict brain metastases in resected early-stage non-small cell lung cancer.一种预测切除的早期非小细胞肺癌脑转移的临床模型。
BMC Cancer. 2025 Feb 11;25(1):236. doi: 10.1186/s12885-025-13609-y.
3
Is the burden of metastatic lymph node stations a prognostic factor in patients with resected lung cancer?

本文引用的文献

1
External validation of the N descriptor in the proposed tumour-node-metastasis subclassification for lung cancer: the crucial role of histological type, number of resected nodes and adjuvant therapy.肺癌拟用的肿瘤-淋巴结-转移亚分类中N描述符的外部验证:组织学类型、切除淋巴结数量及辅助治疗的关键作用
Eur J Cardiothorac Surg. 2020 Dec 1;58(6):1236-1244. doi: 10.1093/ejcts/ezaa215.
2
Prognostic impact of the number of involved lymph node stations in patients with completely resected non-small cell lung cancer: a proposal for future revisions of the N classification.完全切除的非小细胞肺癌患者中受累淋巴结站数的预后影响:对N分类未来修订的建议
Gen Thorac Cardiovasc Surg. 2020 Nov;68(11):1298-1304. doi: 10.1007/s11748-020-01389-0. Epub 2020 May 24.
3
转移性淋巴结站的负担是否是可切除肺癌患者的预后因素?
J Cardiothorac Surg. 2024 Jul 3;19(1):413. doi: 10.1186/s13019-024-02874-w.
4
Development of a predictive model to predict postoperative bone metastasis in pathological I-II non-small cell lung cancer.预测病理I-II期非小细胞肺癌术后骨转移的预测模型的开发。
Transl Lung Cancer Res. 2024 May 31;13(5):998-1009. doi: 10.21037/tlcr-23-866. Epub 2024 May 20.
5
Lymph Node Ratio Enhances Predictive Value for Treatment Outcomes in Patients with Non-Small Cell Lung Cancer Undergoing Surgery: A Retrospective Cohort Study.淋巴结比率提高接受手术的非小细胞肺癌患者治疗结果的预测价值:一项回顾性队列研究
J Cancer. 2024 Jan 1;15(2):466-472. doi: 10.7150/jca.90525. eCollection 2024.
6
[Review for N2 Sub-staging in Non-small Cell Lung Cancer].[非小细胞肺癌N2亚分期的综述]
Zhongguo Fei Ai Za Zhi. 2022 Dec 20;25(12):870-876. doi: 10.3779/j.issn.1009-3419.2022.101.53.
7
A Comprehensive Comparison of Different Nodal Subclassification Methods in Surgically Resected Non-Small-Cell Lung Cancer Patients.不同淋巴结亚分期方法在手术切除的非小细胞肺癌患者中的综合比较。
Ann Surg Oncol. 2022 Dec;29(13):8144-8153. doi: 10.1245/s10434-022-12363-w. Epub 2022 Aug 18.
8
Predictive Risk Factors for Early Recurrence of Stage pIIIA-N2 Non-Small Cell Lung Cancer.pIIIA-N2期非小细胞肺癌早期复发的预测危险因素
Cancer Manag Res. 2021 Nov 18;13:8651-8661. doi: 10.2147/CMAR.S337830. eCollection 2021.
A Comparison of the Currently Used Nodal Stage Classification with the Number of Metastatic Lymph Nodes and the Number of Metastatic Lymph Node Stations for Non-Small Cell Lung Cancer; Which of These Is the Best Prognostic Factor?当前使用的非小细胞肺癌淋巴结分期分类与转移淋巴结数量及转移淋巴结站数的比较;哪一项是最佳预后因素?
Zentralbl Chir. 2020 Dec;145(6):565-573. doi: 10.1055/a-1008-9598. Epub 2019 Oct 24.
4
Recommended Change in the N Descriptor Proposed by the International Association for the Study of Lung Cancer: A Validation Study.国际肺癌研究协会提出的 N 描述符的建议更改:验证研究。
J Thorac Oncol. 2019 Nov;14(11):1962-1969. doi: 10.1016/j.jtho.2019.07.034. Epub 2019 Aug 20.
5
Comparison between lymph node station- and zone-based classification for the future revision of node descriptors proposed by the International Association for the Study of Lung Cancer in surgically resected patients with non-small-cell lung cancer.基于淋巴结站和区的分类比较,用于修订国际肺癌研究协会提出的非小细胞肺癌手术切除患者的淋巴结描述符。
Eur J Cardiothorac Surg. 2019 Nov 1;56(5):849-857. doi: 10.1093/ejcts/ezz147.
6
Proposal of a new nodal classification for operable non-small cell lung cancer based on the number of negative lymph nodes and the anatomical location of metastatic lymph nodes.基于阴性淋巴结数量和转移性淋巴结解剖位置的可手术非小细胞肺癌新的淋巴结分类方案
Medicine (Baltimore). 2019 May;98(20):e15645. doi: 10.1097/MD.0000000000015645.
7
Role of Skip Mediastinal Lymph Node Metastasis for Patients With Resectable Non-small-cell Lung Cancer: A Propensity Score Matching Analysis.可切除非小细胞肺癌患者纵隔淋巴结跳跃转移的作用:倾向评分匹配分析。
Clin Lung Cancer. 2019 May;20(3):e346-e355. doi: 10.1016/j.cllc.2018.12.007. Epub 2018 Dec 19.
8
Log odds of positive lymph nodes may predict survival benefit in patients with node-positive non-small cell lung cancer.淋巴结阳性的非小细胞肺癌患者中,阳性淋巴结的对数比值可能预测生存获益。
Lung Cancer. 2018 Aug;122:60-66. doi: 10.1016/j.lungcan.2018.05.016. Epub 2018 May 23.
9
Lymph node density as a prognostic predictor in patients with betel nut-related oral squamous cell carcinoma.淋巴结密度作为与槟榔相关的口腔鳞状细胞癌患者的预后预测指标。
Clin Oral Investig. 2018 Apr;22(3):1513-1521. doi: 10.1007/s00784-017-2247-3. Epub 2017 Oct 17.
10
A Proposal for Combination of Lymph Node Ratio and Anatomic Location of Involved Lymph Nodes for Nodal Classification in Non-Small Cell Lung Cancer.非小细胞肺癌淋巴结分类中淋巴结比例与阳性淋巴结解剖位置联合应用的建议。
J Thorac Oncol. 2016 Sep;11(9):1565-73. doi: 10.1016/j.jtho.2016.05.004. Epub 2016 May 17.